| DB ID | MyCo_3153 |
| Title | Impact of intravenous and subcutaneous immunoglobulins on false positivity of galactomannan and β-D-glucan antigenaemia and detection of circulating Aspergillus fumigatus DNA |
| Year | 2020 |
| PMID | 32151600 |
| Fungal Diseases involved | Aspergillus fumigatus infection |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | Written informed consent was obtained from pa-tients in accordance with the Ethics Board approval for research on patients cared for by the CEREDIH (CCTIRS 06.327; 7 September 2006). |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | France |
| Cohort | Here collected 21 sets of sera and IVIg samples taken from 18 patients receiving ve different IVIg products |
| Cohort No. | 18 |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | ELISA |
| Analysis Method | FDA Approved-Fungitell assay |
| ELISA kits | Platelia Candida Ag Plus® kit (BioRad, Marnes-la- Coquette,France) |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | FDA Approved-Fungitell assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
